

# Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Information for the public  
Published: 28 March 2024

[www.nice.org.uk](http://www.nice.org.uk)

Olaparib (Lynparza) is available on the NHS. It is a possible treatment for high-grade (fast-growing) advanced ovarian, fallopian tube or peritoneal cancer in adults, if:

- they have a BRCA mutation and
- the cancer has responded to 1 course of platinum-based chemotherapy.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on ovarian cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Ovacome](#), 0800 008 7054
- [Target Ovarian Cancer](#), 0207 923 5475
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5854-2